NASDAQ:OVID - Ovid Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.50
  • Forecasted Upside: 48.03 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.04
▼ -0.01 (-0.33%)

This chart shows the closing price for OVID by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ovid Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OVID and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OVID

Analyst Price Target is $4.50
▲ +48.03% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Ovid Therapeutics in the last 3 months. The average price target is $4.50, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 48.03% upside from the last price of $3.04.

This chart shows the closing price for OVID for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Ovid Therapeutics. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2021JMP SecuritiesReiterated RatingHoldLow
8/25/2021CitigroupLower Price TargetNeutral$4.50 ➝ $4.00Low
4/26/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$8.00 ➝ $4.00N/A
4/20/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$8.00 ➝ $4.00Medium
3/4/2021UBS GroupBoost Price TargetNeutral$4.00 ➝ $5.00Medium
3/3/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$5.00High
12/2/2020Cantor FitzgeraldReiterated RatingOverweightHigh
12/2/2020Royal Bank of CanadaLower Price TargetOutperform$17.00 ➝ $5.00High
12/2/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$10.00 ➝ $40.00High
12/2/2020LADENBURG THALM/SH SHLower Price TargetBuy$21.00 ➝ $7.00High
12/2/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
11/19/2020Royal Bank of CanadaReiterated RatingBuy$17.00Low
10/2/2020William BlairReiterated RatingBuyLow
8/26/2020Cantor FitzgeraldLower Price Target$13.00 ➝ $12.00High
8/26/2020Royal Bank of CanadaBoost Price TargetOutperform$13.00 ➝ $17.00High
8/26/2020CitigroupBoost Price TargetIn-Line ➝ Buy$9.00 ➝ $10.00Medium
8/11/2020William BlairReiterated RatingBuyMedium
7/26/2020Royal Bank of CanadaReiterated RatingBuy$13.00Low
7/17/2020William BlairReiterated RatingBuyLow
7/14/2020CitigroupBoost Price TargetBuy$8.00 ➝ $9.00Medium
7/13/2020LADENBURG THALM/SH SHReiterated RatingBuy$21.00High
6/21/2020Royal Bank of CanadaReiterated RatingBuy$13.00Low
6/18/2020Piper SandlerReiterated RatingOverweight$10.00High
6/18/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
6/18/2020Cantor FitzgeraldBoost Price TargetOverweight$7.00 ➝ $13.00High
3/11/2020William BlairReiterated RatingOutperformHigh
3/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00High
11/22/2019William BlairReiterated RatingBuyLow
11/11/2019CowenReiterated RatingBuyLow
9/24/2019CitigroupBoost Price TargetBuy$8.00 ➝ $10.00High
9/23/2019Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
9/4/2019Royal Bank of CanadaInitiated CoverageOutperform$12.00High
7/1/2019CowenReiterated RatingBuyHigh
5/16/2019LADENBURG THALM/SH SHReiterated RatingBuy$27.00High
5/12/2019CowenReiterated RatingBuyLow
3/10/2019Piper Jaffray CompaniesLower Price TargetOverweight$14.00Low
3/8/2019LADENBURG THALM/SH SHSet Price TargetBuy$27.00Low
3/8/2019JMP SecuritiesLower Price TargetOutperform$26.00 ➝ $11.00Medium
12/17/2018Cantor FitzgeraldSet Price TargetBuy$10.00Medium
12/6/2018Cantor FitzgeraldReiterated RatingBuy$10.00Medium
11/14/2018Cantor FitzgeraldInitiated CoverageOverweightMedium
8/12/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00Low
8/6/2018Piper Jaffray CompaniesSet Price TargetBuy$20.00High
5/20/2018Piper Jaffray CompaniesInitiated CoverageBuy$20.00High
4/20/2018LADENBURG THALM/SH SHInitiated CoverageBuy$27.00Medium
4/1/2018CowenReiterated RatingBuyHigh
3/9/2018Piper Jaffray CompaniesInitiated CoverageOverweight$20.00High
5/30/2017CitigroupInitiated CoverageBuy ➝ Buy$21.00High
5/30/2017William BlairInitiated CoverageOutperform ➝ OutperformHigh
5/30/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$26.00High
5/30/2017CowenInitiated CoverageOutperformHigh
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Ovid Therapeutics logo
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
Read More

Today's Range

Now: $3.04
Low: $3.00
High: $3.15

50 Day Range

MA: $3.30
Low: $3.05
High: $3.64

52 Week Range

Now: $3.04
Low: $2.50
High: $4.80

Volume

210,499 shs

Average Volume

197,108 shs

Market Capitalization

$207.00 million

P/E Ratio

1.70

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Ovid Therapeutics?

The following sell-side analysts have issued reports on Ovid Therapeutics in the last twelve months: Cantor Fitzgerald, Citigroup Inc., JMP Securities, Royal Bank of Canada, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for OVID.

What is the current price target for Ovid Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Ovid Therapeutics in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 47.5%. UBS Group AG has the highest price target set, predicting OVID will reach $5.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $4.00 for Ovid Therapeutics in the next year.
View the latest price targets for OVID.

What is the current consensus analyst rating for Ovid Therapeutics?

Ovid Therapeutics currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OVID, but not buy more shares or sell existing shares.
View the latest ratings for OVID.

How do I contact Ovid Therapeutics' investor relations team?

Ovid Therapeutics' physical mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company's listed phone number is (646) 661-7661 and its investor relations email address is [email protected] The official website for Ovid Therapeutics is www.ovidrx.com.